Anti-Metastasis Fascin Inhibitors Decrease the Growth of Specific Subtypes of Cancers

• Published in: Cancers Vol. 12; no. 8; p. 2287
• Main Authors: Wang, Yufeng, Zhang, J. Jillian, Huang, Xin-Yun
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2020; MDPI
• Subjects: Actin; B-cell lymphoma; Binding sites; Breast cancer; Cancer; Cancer therapies; Cell adhesion & migration; Cell migration; Chemotherapy; Cytoskeleton; Drug dosages; Epidermal growth factor; Epidermal growth factor receptors; fascin; Lungs; Lymphocytes B; Lymphoma; Medical prognosis; Metastases; Metastasis; Pharmacokinetics; Physiological aspects; Tumor cells; tumor metastasis; Tumors; United States
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12082287

Fascin is an actin-bundling protein that is critical for filopodial formation and other cellular cytoskeletal structures. An elevated expression of fascin has been observed in tumor cells and is correlated with a shorter survival of cancer patients. Given its roles in tumor cell migration and invasion, we have developed small-molecule fascin inhibitors to prevent and delay tumor metastasis. Here we report the characterization of a new fascin inhibitor in mice. In addition to its inhibitory effects on tumor metastasis, we also report that fascin inhibitors can decrease the growth of specific subtypes of cancers, including epidermal growth factor receptor (EGFR)-high triple-negative breast cancer, and activated B-cell subtypes of diffuse large B-cell lymphoma. Hence, fascin inhibitors can be used to not only inhibit tumor metastasis, but also decrease the tumor growth of specific cancer types.